A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
Launched by HOFFMANN-LA ROCHE · May 20, 2011
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients, \>/= 18 years of age
- • Metastatic and/or locally advanced malignant CD44-expressing solid tumors
- • Patients with disease progression on standard therapy, or have tumors that are not curable by standard therapy
- • Life expectancy of over 12 weeks
- Exclusion Criteria:
- • Concurrent therapy with any other investigational drug
- • Known or suspected CNS metastases including leptomeningeal metastases
- • Active bleeding, bleeding diathesis or history of coagulation disorder
- • Uncontrolled diabetes mellitus
- • Active or uncontrolled infections
- • Patients with HIV infections
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Houston, Texas, United States
Paris, , France
Toulouse, , France
Seattle, Washington, United States
Nijmegen, , Netherlands
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials